Breaking News, Financial News

Financial Report: Patheon

Patheon

1Q Revenues: $171.7 million (+9%)

1Q Loss: $2.6 million (loss of $11.5 million 1Q2006)

Comments: Revenues from Rx manufacturing services grew 13% to $14.2 million, reflecting higher volumes at the Canadian, European and PR operations. Pharmaceutical development services (PDS) revenues increased 23% to $5 million, due to growth at the Toronto, Cincinnati and Swindon operations. Repositioning expenses — related to workforce reduction and the expansion of the company’s manufacturing efficiency review process — were $3.7 million in the quarter. During the quarter, the company further reduced the size of its global workforce by approximately 300 positions, or 5%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters